Daridorexant hydrochloride is under clinical development by Idorsia Pharmaceutical and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase II drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Daridorexant hydrochloride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Daridorexant hydrochloride overview
Daridorexant Hydrochloride (Quviviq) is under development for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance and post-traumatic stress disorder (PTSD). The drug candidate is a sleep-inducing agent that is administered through oral route in the form of film coated tablets.
Idorsia Pharmaceutical overview
Idorsia Pharmaceutical (Idorsia), a subsidiary of Idorsia Ltd, is a biopharmaceutical company that discovers, develops, and commercializes small molecules. The company’s portfolio products include daridorexant, aprocitentan, lucerastat, sinbaglustat, ACT-777991, ACT-1014-6470, IDOR-1117-2520 and others. Its products treat therapeutic areas such as central nervous system (CNS), cardiovascular, immunological disorders and orphan diseases. Idorsia collaborates with Janssen Biotech to develop and commercialize aprocitentan drug candidates. The company operates through offices in the Netherlands and Switzerland. Idorsia is headquartered in Allschwil, Basel-Landschaft, Switzerland.
For a complete picture of Daridorexant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
